Emerging evidence reveals a clinically significant rebound effect following the discontinuation of glucagon-like peptide-1 ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) ...

The National Institute for Health and Care Excellence (NICE) has published updated guidance recommending Forxiga ...

What else is there to share? As it happens, quite a lot. Last time I spoke about the diagnosis of Young Onset Parkinson’s disease (YOPD), how this presented several day-to-day challenges from securing ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...

The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research ...

TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share ...

The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...

With over 55 million people worldwide living with dementia, Oxford Brain Diagnostics (OBD) is set to revolutionise early ...

The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time, marking a ...

The study met its primary endpoint, with a statistically significant placebo-adjusted 61% and 58% reduction in triglyceride ...

Worldwide Clinical Trials has appointed Stephen Rayda as its first Chief Digital and Information Officer, expanding the ...